Compare Stocks: LAB, CYRX, DNA, and PACB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYRX CryoPort	$17.35 +2.7%	$16.29	$7.61 ▼ $18.36	$855.97M	1.96	798,302 shs	479,869 shs
DNA Ginkgo Bioworks	$12.95 +14.2%	$8.56	$5.37 ▼ $18.22	$763.64M	1.79	3.41 million shs	4.51 million shs
LAB Standard BioTools	$0.69 +2.8%	$0.72	$0.63 ▼ $1.72	$263.15M	1.36	1.06 million shs	649,202 shs
PACB Pacific Biosciences of California	$2.33 +1.3%	$1.54	$1.07 ▼ $3.43	$714.91M	2.19	18.55 million shs	12.81 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYRX CryoPort	+2.66%	-0.46%	+14.60%	+7.30%	+72.47%
DNA Ginkgo Bioworks	+13.85%	+4.95%	+91.12%	+42.31%	-19.52%
LAB Standard BioTools	+2.85%	-7.43%	-5.17%	-24.93%	-47.77%
PACB Pacific Biosciences of California	+1.30%	-8.27%	+80.62%	+49.36%	+54.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYRX CryoPort	$17.35 +2.7%	$16.29	$7.61 ▼ $18.36	$855.97M	1.96	798,302 shs	479,869 shs
DNA Ginkgo Bioworks	$12.95 +14.2%	$8.56	$5.37 ▼ $18.22	$763.64M	1.79	3.41 million shs	4.51 million shs
LAB Standard BioTools	$0.69 +2.8%	$0.72	$0.63 ▼ $1.72	$263.15M	1.36	1.06 million shs	649,202 shs
PACB Pacific Biosciences of California	$2.33 +1.3%	$1.54	$1.07 ▼ $3.43	$714.91M	2.19	18.55 million shs	12.81 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYRX CryoPort	+2.66%	-0.46%	+14.60%	+7.30%	+72.47%
DNA Ginkgo Bioworks	+13.85%	+4.95%	+91.12%	+42.31%	-19.52%
LAB Standard BioTools	+2.85%	-7.43%	-5.17%	-24.93%	-47.77%
PACB Pacific Biosciences of California	+1.30%	-8.27%	+80.62%	+49.36%	+54.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYRX CryoPort	2.78	Moderate Buy	$18.38	5.91% Upside
DNA Ginkgo Bioworks	1.50	Reduce	$6.33	-51.09% Downside
LAB Standard BioTools	1.67	Reduce	$1.35	95.82% Upside
PACB Pacific Biosciences of California	1.83	Reduce	$1.71	-26.50% Downside

Current Analyst Ratings Breakdown

Latest LAB, CYRX, DNA, and PACB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	CYRX CryoPort	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
10/1/2026	CYRX CryoPort	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$16.00 ➝ $19.00
9/28/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/18/2026	CYRX CryoPort	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/10/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	DNA Ginkgo Bioworks	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.00
9/9/2026	PACB Pacific Biosciences of California	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$1.50 ➝ $1.35
9/4/2026	DNA Ginkgo Bioworks	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell	$5.00
8/25/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	CYRX CryoPort	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/17/2026	DNA Ginkgo Bioworks	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYRX CryoPort	$176.18M	4.99	N/A	N/A	$9.19 per share	1.89
DNA Ginkgo Bioworks	$170.15M	5.13	N/A	N/A	$8.74 per share	1.48
LAB Standard BioTools	$84.60M	3.20	N/A	N/A	$1.10 per share	0.63
PACB Pacific Biosciences of California	$160.01M	4.53	$0.80 per share	2.91	$0.02 per share	116.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYRX CryoPort	$78.30M	-$0.90	N/A	N/A	N/A	-20.05%	-7.20%	-4.30%	11/3/2026 (Estimated)
DNA Ginkgo Bioworks	-$312.76M	-$5.01	N/A	N/A	N/A	-259.96%	-60.27%	-26.88%	11/5/2026 (Estimated)
LAB Standard BioTools	-$74.90M	$0.22	3.13	N/A	N/A	100.36%	-7.57%	-6.14%	11/3/2026 (Estimated)
PACB Pacific Biosciences of California	-$546.38M	-$0.43	N/A	N/A	N/A	-82.49%	-5,752.12%	-19.52%	11/3/2026 (Estimated)

Latest LAB, CYRX, DNA, and PACB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	DNA Ginkgo Bioworks	-$0.58	N/A	N/A	N/A	$21.57 million	N/A
11/3/2026	Q3 2026	CYRX CryoPort	-$0.19	N/A	N/A	N/A	$48.69 million	N/A
11/3/2026	Q3 2026	LAB Standard BioTools	-$0.02	N/A	N/A	N/A	$18.80 million	N/A
11/3/2026	Q3 2026	PACB Pacific Biosciences of California	-$0.1260	N/A	N/A	N/A	$43.82 million	N/A
8/6/2026	Q2 2026	CYRX CryoPort	-$0.1933	-$0.20	-$0.0067	-$0.20	$48.18 million	$48.97 million
8/5/2026	Q2 2026	DNA Ginkgo Bioworks	-$0.8950	-$0.75	+$0.1450	-$0.75	$24.05 million	$20.16 million
8/5/2026	Q2 2026	LAB Standard BioTools	-$0.0128	-$0.07	-$0.0573	-$0.07	$20.80 million	$20.10 million
8/3/2026	Q2 2026	PACB Pacific Biosciences of California	-$0.1280	-$0.14	-$0.0120	-$0.14	$42.90 million	$39.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
LAB Standard BioTools	N/A	N/A	N/A	N/A	N/A
PACB Pacific Biosciences of California	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYRX CryoPort	N/A	2.08	1.98
DNA Ginkgo Bioworks	N/A	4.57	4.57
LAB Standard BioTools	N/A	9.10	8.80
PACB Pacific Biosciences of California	N/A	4.92	4.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYRX CryoPort	92.90%
DNA Ginkgo Bioworks	78.63%
LAB Standard BioTools	53.74%
PACB Pacific Biosciences of California	N/A

Insider Ownership

Company	Insider Ownership
CYRX CryoPort	9.50%
DNA Ginkgo Bioworks	12.69%
LAB Standard BioTools	26.81%
PACB Pacific Biosciences of California	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYRX CryoPort	738	50.65 million	45.84 million	Optionable
DNA Ginkgo Bioworks	485	67.34 million	58.80 million	Optionable
LAB Standard BioTools	389	392.58 million	287.33 million	Optionable
PACB Pacific Biosciences of California	485	310.83 million	299.33 million	Optionable

LAB, CYRX, DNA, and PACB Headlines

Recent News About These Companies

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Has Consensus Price Target of $1.71 According to Brokerages

October 10 at 4:43 AM | marketbeat.com

Pacific Biosciences of California (NASDAQ:PACB) Stock: Insider James Gibson II Sells 661,815 Shares

October 10 at 4:09 AM | americanbankingnews.com

Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 661,815 Shares of Company Stock

October 9 at 5:52 AM | insidertrades.com

PacBio (PACB) Stock Gets Fair Value Boost After UBS Starts Coverage Neutral

October 9 at 1:21 AM | finance.yahoo.com

Barclays keeps Sell rating for Pacific Biosciences stock

October 8 at 8:20 PM | ad-hoc-news.deA

Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today

October 8 at 7:16 PM | zacks.com

Pacific Biosciences of California (NASDAQ:PACB) Insider James Gibson II Sells 661,815 Shares of Stock

October 8 at 5:07 PM | marketbeat.com

Pacific Biosciences of California (NASDAQ:PACB) Shares Down 6.9% - Time to Sell?

October 7 at 12:20 PM | marketbeat.com

Pacific Biosciences Collaborates With TychoBio For AI-powered RNA Data Creation; Shares Up

October 6, 2026 | rttnews.com

Pacific Biosciences of California, TychoBio Collaborate to Generate Full-Length RNA Data for AI Model Training

October 6, 2026 | finance.yahoo.com

PacBio Slides as Recent Rally Cools and Investors Reassess Turnaround Risks

October 6, 2026 | quiverquant.comQ

Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up - Still a Buy?

October 6, 2026 | marketbeat.com

PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics

October 6, 2026 | globenewswire.com

Pacific Biosciences stock hits a new 52-week high

October 5, 2026 | ad-hoc-news.deA

Pacific Biosciences of California (NASDAQ:PACB) Hits New 52-Week High - Should You Buy?

October 5, 2026 | marketbeat.com

Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts

October 2, 2026 | zacks.com

Average analyst price target for Pacific Biosciences of California decreases 28.85% to MX$38.33

October 2, 2026 | msn.com

Pacific Biosciences of California (NASDAQ:PACB) Sees Unusually-High Trading Volume - What's Next?

October 2, 2026 | americanbankingnews.com

Pacific Biosciences: Stock Surges As New Use Case Seen - But Caution Is Warranted

October 1, 2026 | seekingalpha.com

3 Biotech Stocks Put Traders Are Targeting Today

October 1, 2026 | schaeffersresearch.com

Bank of America Corp DE Makes New Investment in Pacific Biosciences of California, Inc. $PACB

October 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LAB, CYRX, DNA, and PACB Company Descriptions

CryoPort NASDAQ:CYRX

$17.35 +0.45 (+2.66%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$17.34 -0.01 (-0.03%)

As of 10/9/2026 07:30 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Ginkgo Bioworks NYSE:DNA

$12.95 +1.61 (+14.20%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$13.02 +0.07 (+0.54%)

As of 10/9/2026 07:59 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Standard BioTools NASDAQ:LAB

$0.69 +0.02 (+2.85%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.71 +0.02 (+3.57%)

As of 10/9/2026 07:38 PM Eastern

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Pacific Biosciences of California NASDAQ:PACB

$2.33 +0.03 (+1.30%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.33 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LAB, CYRX, DNA, and PACB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LAB, CYRX, DNA, and PACB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LAB, CYRX, DNA, and PACB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LAB, CYRX, DNA, and PACB Company Descriptions

CryoPort NASDAQ:CYRX

Ginkgo Bioworks NYSE:DNA

Standard BioTools NASDAQ:LAB

Pacific Biosciences of California NASDAQ:PACB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LAB, CYRX, DNA, and PACB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LAB, CYRX, DNA, and PACB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LAB, CYRX, DNA, and PACB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LAB, CYRX, DNA, and PACB Company Descriptions

CryoPort NASDAQ:CYRX

Ginkgo Bioworks NYSE:DNA

Standard BioTools NASDAQ:LAB

Pacific Biosciences of California NASDAQ:PACB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools